These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 1993850)

  • 1. Evidence for the functional binding in vivo of tumor rejection antigens to antigen-presenting cells in tumor-bearing hosts.
    Shimizu J; Zou JP; Ikegame K; Katagiri T; Fujiwara H; Hamaoka T
    J Immunol; 1991 Mar; 146(5):1708-14. PubMed ID: 1993850
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of tumor-specific in vivo protective immunity by immunization with tumor antigen-pulsed antigen-presenting cells.
    Shimizu J; Suda T; Yoshioka T; Kosugi A; Fujiwara H; Hamaoka T
    J Immunol; 1989 Feb; 142(3):1053-9. PubMed ID: 2464022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of tumor-specific in vivo protective immunity by immunization with tumor antigen-pulsed antigen-presenting cells.
    Hamaoka T; Shimizu J; Suda T; Fujiwara H
    Princess Takamatsu Symp; 1988; 19():265-75. PubMed ID: 3269360
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor-bearing mice exhibit a progressive increase in tumor antigen-presenting cell function and a reciprocal decrease in tumor antigen-responsive CD4+ T cell activity.
    Zou JP; Shimizu J; Ikegame K; Yamamoto N; Ono S; Fujiwara H; Hamaoka T
    J Immunol; 1992 Jan; 148(2):648-55. PubMed ID: 1345922
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo treatment with monoclonal anti-I-A antibodies: disappearance of splenic antigen-presenting cell function concomitant with modulation of splenic cell surface I-A and I-E antigens.
    Kruisbeek AM; Titus JA; Stephany DA; Gause BL; Longo DL
    J Immunol; 1985 Jun; 134(6):3605-14. PubMed ID: 2580891
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antigen-presenting cells constitutively bind tumor antigens in the tumor-bearing state in vivo to construct an effective immunogenic unit.
    Shimizu J; Zou JP; Ikegame K; Fujiwara H; Hamaoka T
    Jpn J Cancer Res; 1991 Mar; 82(3):262-5. PubMed ID: 1902448
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced induction of antitumor T-cell responses by cytotoxic T lymphocyte-associated molecule-4 blockade: the effect is manifested only at the restricted tumor-bearing stages.
    Yang YF; Zou JP; Mu J; Wijesuriya R; Ono S; Walunas T; Bluestone J; Fujiwara H; Hamaoka T
    Cancer Res; 1997 Sep; 57(18):4036-41. PubMed ID: 9307290
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cell-mediated immune responses to syngeneic ultraviolet-induced tumours. V. Assessment of accessory and antigen-presenting cell capabilities of normal and ultraviolet-irradiated mice in the generation of anti-tumour cytotoxic effector cells in vitro.
    Lynch DH; Gurish MF; Daynes RA
    Immunology; 1982 Sep; 47(1):49-59. PubMed ID: 6981587
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A role of interferon-gamma (IFN-gamma) in tumor immunity: T cells with the capacity to reject tumor cells are generated but fail to migrate to tumor sites in IFN-gamma-deficient mice.
    Nakajima C; Uekusa Y; Iwasaki M; Yamaguchi N; Mukai T; Gao P; Tomura M; Ono S; Tsujimura T; Fujiwara H; Hamaoka T
    Cancer Res; 2001 Apr; 61(8):3399-405. PubMed ID: 11309299
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo treatment with anti-I-A antibodies: differential effects on Ia antigens and antigen-presenting cell function of spleen cells and epidermal Langerhans cells.
    Aberer W; Kruisbeek AM; Shimada S; Katz SI
    J Immunol; 1986 Feb; 136(3):830-6. PubMed ID: 3455705
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A pivotal role for CC chemokine receptor 5 in T-cell migration to tumor sites induced by interleukin 12 treatment in tumor-bearing mice.
    Uekusa Y; Yu WG; Mukai T; Gao P; Yamaguchi N; Murai M; Matsushima K; Obika S; Imanishi T; Higashibata Y; Nomura S; Kitamura Y; Fujiwara H; Hamaoka T
    Cancer Res; 2002 Jul; 62(13):3751-8. PubMed ID: 12097285
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recovery of antitumor CD4+ T cell responsiveness, suppressed in the tumor-bearing state, by release from tumor burden.
    Zou JP; Nagata T; Yamamoto N; Ono S; Fujiwara H; Hamaoka T
    J Cancer Res Clin Oncol; 1994; 120(5):279-85. PubMed ID: 7907334
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Administration of IL-12 induces a CD3+ CD4- CD8- B220+ lymphoid population capable of eliciting cytolysis against Fas-positive tumor cells.
    Tsutsui T; Mu J; Ogawa M; Yu WG; Suda T; Nagaga S; Saji F; Murata Y; Fujiwara H; Hamaoka T
    J Immunol; 1997 Sep; 159(6):2599-605. PubMed ID: 9300678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tolerance induction of allo-class II H-2 antigen-reactive L3T4+ helper T cells and prolonged survival of the corresponding class II H-2-disparate skin graft.
    Hori S; Sato S; Kitagawa S; Azuma T; Kokudo S; Hamaoka T; Fujiwara H
    J Immunol; 1989 Sep; 143(5):1447-52. PubMed ID: 2527264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytotoxic T-cell-mediated antitumor effect of levamisole against murine syngeneic fibrosarcoma.
    Gomi K; Morimoto M; Nomoto K
    Cancer Res; 1982 Oct; 42(10):4197-202. PubMed ID: 6980702
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Biochemical characterization of tumor rejection antigen (TRA) and genetic control in anti-TRA immune responses].
    Fujiwara H; Suda T; Shimizu J; Muramatsu M; Kimura K; Hamaoka T
    Gan To Kagaku Ryoho; 1989 Mar; 16(3 Pt 2):646-52. PubMed ID: 2468311
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An essential role of antigen-presenting cell/T-helper type 1 cell-cell interactions in draining lymph node during complete eradication of class II-negative tumor tissue by T-helper type 1 cell therapy.
    Chamoto K; Wakita D; Narita Y; Zhang Y; Noguchi D; Ohnishi H; Iguchi T; Sakai T; Ikeda H; Nishimura T
    Cancer Res; 2006 Feb; 66(3):1809-17. PubMed ID: 16452242
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiple roles of interferon-gamma in the mediation of interleukin 12-induced tumor regression.
    Ogawa M; Yu WG; Umehara K; Iwasaki M; Wijesuriya R; Tsujimura T; Kubo T; Fujiwara H; Hamaoka T
    Cancer Res; 1998 Jun; 58(11):2426-32. PubMed ID: 9622084
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms of in vivo generation of cytotoxic effector cells against tumor in tumor-bearing mice.
    Fuyama S; Yamamoto H; Fujii Y; Arai S
    Cancer Res; 1986 Nov; 46(11):5548-52. PubMed ID: 2428480
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Enhancement of T cell-mediated immune responses in KMT-17-bearing rats by treatment with bleomycin].
    Xu ZY
    Hokkaido Igaku Zasshi; 1987 Mar; 62(2):279-88. PubMed ID: 2440789
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.